Medrobotics develops and markets the Flex Robotic System, a steerable and shapeable robotic scope that enables surgeons to navigate complex anatomy through a single, small entry point. The Flex System is described as the world’s first and only robotic surgical platform providing Scarfree™ access in otolaryngology and colorectal procedures and has received FDA clearances for ENT and colorectal uses. The system was also cleared for robot-assisted visualization in general surgical, gynecological and thoracic procedures in the U.S., and holds a CE mark. Medrobotics is pursuing expanded applications including transvaginal gynecologic procedures and single-port abdominal applications in general surgery, urology and gynecology. The company is privately funded and headquartered in Raynham, Massachusetts. It recently announced a $25 million venture debt investment commitment to support product development and manufacturing expansion. Medrobotics manufactures and markets the Flex® Robotic System, a minimally-invasive, robot-assisted platform that allows surgeons to access, visualize, and deliver instruments to anatomical locations that are hard to reach with traditional methods. The company is led by President & CEO Samuel F. Straface, Ph.D., and is based in Raynham, Massachusetts. Medrobotics received FDA clearance for the Flex® Robotic System in 2015 and the CE mark in 2014. It closed a $25M financing in which existing shareholders participated. The company intends to use the funds to expand commercial efforts for the Flex® Robotic System. No revenue or user metrics were disclosed in the article. Medrobotics Corporation is a privately-held surgical products company headquartered in Raynham, Massachusetts that develops the Flex System, a robot-assisted flexible endoscopic platform, and the Flex Retractor. The Flex System provides surgeons single-site access and visualization of hard-to-reach anatomical locations, while the Flex Retractor is designed to facilitate exposure in advanced transoral surgeries. This year the company received CE marks for both the Flex System and the Flex Retractor and has met applicable FDA requirements to distribute the Flex Retractor in the U.S.; the Flex System is not currently cleared for sale in the U.S. Medrobotics closed a $20 million preferred stock financing with participation from existing shareholders to extend its runway. Proceeds will be used to support commercial launches in Europe and to prepare for FDA clearance and broader commercialization in the United States and other global markets. The company positions its products as affordable options for minimally invasive surgery that can reduce hospital stays, costs, and recovery times. Medrobotics is a privately-held surgical products company headquartered in Raynham, Massachusetts that develops and commercializes the Flex® System, a robot-assisted flexible endoscopic platform. The Flex® System received the CE mark and is designed to provide single-site access and visualization of hard-to-reach anatomical locations, enabling surgeons to navigate around anatomical structures and deploy flexible instruments using onboard high-definition vision. The company’s 3mm wristed Flex® Instruments have also received the CE mark. Medrobotics says it will use financing proceeds for regulatory preparations and submissions and for anticipated commercial launches in Europe and the United States. The platform aims to expand minimally invasive options where conventional line-of-sight technologies are infeasible or sub-optimal, potentially reducing hospital stays and recovery times. These products are not currently approved for sale in the U.S. Medrobotics Corporation, based in Raynham, Massachusetts, is developing and commercializing the Flex™ Robotic System. The Flex™ Robotic System is a robotic-assist platform that enables surgeons to gain single-site access and visualization to difficult-to-access anatomical locations. The system provides a precise and stable platform for enhanced visualization and enables two-handed dexterity with compatible third-party instruments having tactile feedback. The company is privately held and is preparing anticipated commercial launches in Europe and the United States. To support those launches, Medrobotics closed up to $10 Million in new debt financing.

Total raised

$163M

Funding rounds

8

Latest round

Debt Financing

Latest activity

Jun 2018